Studies on Non-Thiazolidinedione Antidiabetic Agents. 1. Discovery of Novel Oxyiminoacetic Acid Derivatives.
作者:Hiroshi Imoto、Eikoh Imamiya、Yu Momose、Yasuo Sugiyama、Hiroyuki Kimura、Takashi Sohda
DOI:10.1248/cpb.50.1349
日期:——
A novel series of oxyiminoacetic acid derivatives were synthesized in an effort to develop a potent antidiabetic agent, which does not contain the 2,4-thiazolidinedione moiety. These compounds were evaluated for glucose and lipid lowering effects in genetically obese and diabetic KKAy mice. Several of the compounds showed strong antidiabetic activity, including functional potency at peroxisome proliferator-activated receptor (PPAR)-γ. (Z)-2-[4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino]-2-(4-phenoxyphenyl)acetic acid (25) significantly reduced plasma glucose (33%, p<0.01) and plasma triglycelide levels (43%, p<0.01) even at a dosage of 0.001% in diet. Pharmacokinetic analyses of 25 are also reported.
合成了一系列新型氧亚氨基乙酸衍生物,旨在开发不含有2,4-噻唑烷二酮部分的强效抗糖尿病药物。这些化合物在遗传性肥胖和糖尿病的KKAy小鼠中评估了其降低血糖和血脂的效果。其中几种化合物显示出强大的抗糖尿病活性,包括在过氧化物酶体增殖物激活受体(PPAR)-γ上的功能活性。(Z)-2-[4-[(5-甲基-2-苯基-1,3-噁唑-4-基)甲氧基]苄氧亚氨基]-2-(4-苯氧基苯基)乙酸(25)即使在饮食中含量仅为0.001%的剂量下,也能显著降低血浆葡萄糖水平(33%,p<0.01)和血浆甘油三酯水平(43%,p<0.01)。同时还报道了25的药代动力学分析。